Updates are available Correction dated 2023-01-03
Click to view Correction: https://doi.org/10.1038/s41409-022-01891-4
-
Authors
Kansagra, Ankit J.
Frey, Noelle V.
Bar, Merav
Laetsch, Theodore W.
Carpenter, Paul A.
Savani, Bipin N.
Heslop, Helen E.
Bollard, Catherine M.
Komanduri, Krishna V.
Gastineau, Dennis A.
Chabannon, Christian http://orcid.org/0000-0002-3755-4889
Perales, Miguel A.
Hudecek, Michael
Aljurf, Mahmoud
Andritsos, Leslie
Barrett, John A.
Bachanova, Veronika http://orcid.org/0000-0002-9325-432X
Bonini, Chiara
Ghobadi, Armin
Gill, Saar I.
Hill, Joshua A. http://orcid.org/0000-0002-7665-7100
Kenderian, Saad
Kebriaei, Partow
Nagler, Arnon
Maloney, David
Liu, Hien D.
Shah, Nirali N.
Kharfan-Dabaja, Mohamed A.
Shpall, Elizabeth J.
Mufti, Ghulam J.
Johnston, Laura
Jacoby, Elad http://orcid.org/0000-0003-1411-8942
Bazarbachi, Ali
DiPersio, John F.
Pavletic, Steven Z.
Porter, David L.
Grupp, Stephan A.
Sadelain, Michel
Litzow, Mark R.
Mohty, Mohamad
Hashmi, Shahrukh K.
- License Information
-
More Information
Article History
Received: 10 December 2018
Accepted: 24 December 2018
First Online: 15 May 2019
Change Date: 3 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-022-01891-4
Compliance with ethical standards
:
: AJK: Scientific Advisory Board–Celgene. NVF: Consultant–Novartis, Servier. TWL: Consultant–Novartis CMB: Scientific Advisory Boards: Cellectis. Stock/ownership: Mana Therapeutics, Torque and Neximmune. KK: Scientific Advisory Boards: Kite/Gilead, Novartis, Juno/Celgene, Atara, Takeda; Clinical Research Site: Kite, Iovance, Juno, Atara. CC: Consultant–Gilead, Research Funding: Gilead, Celgene, Speaker: Terumo BCT, Novartis. MAP: Honorarium: Abbvie, Bellicum, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda. Data Safety Monitoring Board: Servier and Medigene, Scientific Advisory Boards–MolMed and NexImmune. Research Funding–Incyte, Miltenyi Biotec. LA: Board of director/Scientific Advisory Board: HCLF, Consultant: AstraZeneca. VB: Research Funding–Gamida Cell, GT Biopharma, Scientific Advisory Board - Novartis, Kite, Travel funding–Amgen. CB: Research Funding–Intellia Therapeutics, Scientific Advisory Boards - TxCell, MolMed s.p.a., Travel funding–Miltenyi. SAG: Research Funding–Novartis, Servier and Kite. Consultant/Study Steering Committees/Scientific Advisory Boards–Novartis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Cellectis, Vertex, and Roche. JAH: Consultant–Nohla Therapeutics, inc. and Amplyx, Research Funding–Karius and Shire. SK: Research funding: Humanigen, Tolero, Lentigen. Patents and Royalites: Novartis. DM: Scientific Advisory Board: Janssen, Honoraria: Seattle Genetics, Roche/Genentech, Research Funding: Juno Therapeutics, GlaxoSmithKline. MAK: Consultant–Pharmacyclics, Speaker–Incyte Corp, Seattle Genetics and Alexion Pharmaceuticals. EJ: Scientific Advisory Boards–Novartis. Speaker: Medison. AB: Scientific Advisory Boards–Novartis, Roche, Sanofi, Jazz, Adienne, Pfizer, Amgen. Research Funding: Novartis, Amgen, Takeda, Astellas, Celgene, Pfizer. JFD: Ownership/Equity–WUGEN. DLP: Research Funding–Novartis, Scientific Advisory Boards - Novartis, Kite, Patent and Royalty payments–Novartis. SIG: Research Funding–Novartis; Tmunity Therapeutics. Scientific Advisory Boards–Aileron; Fate Therapeutics; Intellia. Patent and Royalties–Novartis. Ownership/equity–Carisma Therapeutics. MS: Research Funding: Fate Theapeutics Inc, Consultant/Board of Director/Scientific Advisory Board/Patents and Royalties/Research Funding: Juno Therapeutics, MM: Lecture honoraria and Consultant- Novartis, Amgen and Pfizer. SKH: Honorarium: Mallinckrodt
